HDX-MS Epitope Mapping for Antibody-Antigen Interaction Analysis

Standard HDX-MS achieves peptide-level resolution of 5–15 amino acids, which is typically sufficient to define the epitope surface region on the folded antigen. For higher resolution, ETD (electron transfer dissociation) fragmentation can localize deuterium incorporation to 1–3 residues within a peptide — though this requires sufficient peptide ion signal and is applied on a case-by-case basis. The practical resolution of your epitope map depends on sequence coverage and peptide redundancy in the epitope region, which we maximize through multi-protease digestion strategies and in silico feasibility assessment before experiments begin.

HDX-MS alone cannot definitively distinguish residues directly involved in the binding interface from those undergoing allosteric conformational changes upon binding — both result in deuterium uptake protection. This is a well-recognized limitation of the technique. For programs where this distinction is critical, we recommend combining HDX-MS with orthogonal crosslinking-MS (XL-MS), which provides residue-pair distance constraints that directly identify interface contacts, or with site-directed mutagenesis of candidate epitope residues identified by HDX-MS.

We routinely analyze soluble proteins, membrane proteins (GPCRs, ion channels, transporters), heavily glycosylated proteins (viral spike antigens, therapeutic glycoproteins), intrinsically disordered proteins, multi-subunit complexes, and nucleic acid–protein complexes. For membrane proteins, we optimize detergent conditions to maintain protein stability while minimizing interference with pepsin digestion and chromatography. Glycosylated targets benefit from in-house deglycosylation (PNGase F/A/H+) to improve sequence coverage in glycosylated regions. Our team will assess your specific target during project consultation and recommend any required protocol adaptations.

A standard single-antibody epitope mapping experiment requires 0.5–1 mg of purified antigen at ≥90% purity and an approximately equivalent mass of purified antibody. Accelerated epitope screening (binning) requires proportionally less per antibody candidate. Standard turnaround is 3–4 weeks from sample acceptance to delivery of the interpreted epitope map. Buffer incompatibility is the most common cause of delay — we provide a buffer screening consultation before sample shipment to identify issues proactively.

Yes. HDX-MS epitope mapping data are routinely included in antibody patent applications to define the binding interface compositionally and structurally. For biosimilar programs, differential HDX-MS comparing innovator vs. biosimilar antibody-antigen complexes provides experimental evidence of epitope equivalence that supports the demonstration of structural similarity. Our deliverables include publication-quality figures (Woods plots, differential heat maps, 3D PyMOL visualizations) and a comprehensive methods section suitable for inclusion in manuscripts and regulatory documentation.

We perform in silico pepsin digestion during project consultation to assess expected coverage of your antigen. If coverage gaps are predicted in critical regions (e.g., CDR loops, known epitope hotspots), we deploy a multi-protease strategy — supplementing pepsin with alternative proteases (e.g., protease type XIII, Nepenthesin-1) and/or applying TCEP reduction to improve coverage of disulfide-bonded regions. For glycosylated antigens, enzymatic deglycosylation often reveals previously inaccessible peptides. In our experience, >85% coverage is routinely achievable; >90% is typical for optimized targets.

Computational epitope prediction tools (Discotope, EpiPred, ClusPro, HADDOCK) can generate hypotheses, but they are not substitutes for experimental data. Prediction accuracy varies significantly by antigen class, and tools trained on antibody-antigen crystal structures may underperform on flexible or non-crystallizable targets. HDX-MS provides direct experimental measurement of the antibody-protected surface — orthogonal to and more reliable than prediction alone. The strongest approach combines HDX-MS data with computational docking: HDX-defined protection regions serve as experimental restraints in RosettaDock or HADDOCK to generate residue-level epitope models. For orthogonal binding validation, complementary techniques such as surface plasmon resonance (SPR) and biolayer interferometry (BLI) provide real-time kinetic confirmation of the binding affinity. Our team can coordinate this integrative, multi-technique analysis upon request.